Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1726)	7/28/2003 12:45:22 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Alnylam Pharmaceuticals Appoints Dr. Vincent Miles as Head of Business Development Monday July 28, 8:35 am ET [Somewhat leaky at present, it seems] CAMBRIDGE, Mass., July 28 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc., the leading therapeutic RNA interference (RNAi) company, today announced the appointment of Vincent J. Miles, Ph.D., as Senior Vice President of Business Development. Dr. Miles has more than 25 years of experience in business and R&D roles with biotechnology companies. In his position at Alnylam, Dr. Miles will lead the company's business development initiatives and will serve as a member of the company's management team, reporting to John Maraganore, president and CEO. "Alnylam is delighted to welcome Vin, who brings to our team extensive experience in creating world class partnerships with leading pharmaceutical and biotech companies" said Dr. John Maraganore, President and CEO of Alnylam. "He has the unique skills to help Alnylam accelerate its commercial success through global partnerships that effectively advance RNAi-based therapeutics to the marketplace." Dr. Miles was formerly Vice President of Business Development at Millennium Pharmaceuticals, where he worked since 1997 and played a leadership role in the formation of ground-breaking alliances with pharmaceutical and technology companies worth over $1 billion. He has extensive experience in establishing strategic partnerships and securing in-licensing and out- licensing transactions in his tenure at Millennium, as well as in previous business development positions at the Dana-Farber Cancer Institute and RiboGene, Inc. Earlier in his career, he held product development and marketing roles with Pharmacia Biotech, and Amersham Corporation. Dr. Miles has served in various senior management roles, and has been actively involved in strategic business planning, corporate communications, and financing and investor activities. Dr. Miles received his bachelor's degree in biochemistry and his Ph.D. in molecular biology from University College London.